Anest. intenziv. Med. 2023;34(4):152-156 | DOI: 10.36290/aim.2023.053

Five most important drug interactions in the critically illReview Article

Rychlíčková J.1, 2, Suk P.1, 3
1 International Clinical Research Center, Fakultní nemocnice u sv. Anny v Brně, Brno
2 Farmakologický ústav, Lékařská fakulta, Masarykova univerzita, Brno
3 Anesteziologicko­‑resuscitační klinika, FN u sv. Anny v Brně a Lékařská fakulta, Masarykova univerzita, Brno

The prevalence of drug interactions in the critically ill is high, but these are often potential drug interactions of limited clinical relevance. This paper aims to describe the mechanism and management of not the most frequent but, according to the authors, the most clinically significant interactions. These top five interactions include carbapenems and valproate, CYP 3A4 inhibitors and ticagrelor, enteral nutrition and levodopa, combinations of QT prolonging drugs, and CYP 3A4 inhibitors and quetiapine.

Keywords: drug interactions, critical care, drug side effects, long QT syndrome, cytochrome P-450 enzyme enhibitors.

Received: August 28, 2023; Revised: October 31, 2023; Accepted: November 7, 2023; Prepublished online: November 29, 2023; Published: December 15, 2023  Show citation

ACS AIP APA ASA Harvard Chicago Chicago Notes IEEE ISO690 MLA NLM Turabian Vancouver
Rychlíčková J, Suk P. Five most important drug interactions in the critically ill. Anest. intenziv. Med. 2023;34(4):152-156. doi: 10.36290/aim.2023.053.
Download citation

References

  1. Bakker T, Abu­‑Hanna A, Dongelmans DA, Vermeijden WJ, Bosman RJ, de Lange DW, et al. Clinically relevant potential drug­‑drug interactions in intensive care patients: A large retrospective observational multicenter study. J Crit Care. 2021 Apr;62:124-30. Go to original source... Go to PubMed...
  2. Wong A, Amato MG, Seger DL, Rehr C, Wright A, Slight SP, et al. Prospective evaluation of medication­‑related clinical decision support over­‑rides in the intensive care unit. BMJ Qual Saf. 2018 Sep;27(9):718-24. Go to original source... Go to PubMed...
  3. Fitzmaurice MG, Wong A, Akerberg H, Avramovska S, Smithburger PL, Buckley MS, et al. Evaluation of Potential Drug-Drug Interactions in Adults in the Intensive Care Unit: A Systematic Review and Meta­‑Analysis. Drug Saf. 2019 Sep 1;42(9):1035-44. Go to original source... Go to PubMed...
  4. Zheng WY, Richardson LC, Li L, Day RO, Westbrook JI, Baysari MT. Drug­‑drug interactions and their harmful effects in hospitalised patients: a systematic review and meta­‑analysis. Eur J Clin Pharmacol. 2018 Jan 1;74(1):15-27. Go to original source... Go to PubMed...
  5. Hsiao SC, Lai WH, Chen IL, Shih FY. Clinical impact of carbapenems in critically ill patients with valproic acid therapy: A propensity­‑matched analysis. Front Neurol. 2023 Mar 9;14:1069742. Go to original source... Go to PubMed...
  6. Mancl EE, Gidal BE. The effect of carbapenem antibiotics on plasma concentrations of valproic acid. Ann Pharmacother. 2009;43(12):2082-7. Go to original source... Go to PubMed...
  7. Al­‑Quteimat O, Laila A. Valproate Interaction With Carbapenems: Review and Recommendations. Hosp Pharm. 2020 Jun;55(3):181-7. Go to original source... Go to PubMed...
  8. Huang CR, Lin CH, Hsiao SC, Chen NC, Tsai WC, Chen SD, et al. Drug interaction between valproic acid and carbapenems in patients with epileptic seizures. Kaohsiung J Med Sci. 2017 Mar;33(3):130-6. Go to original source... Go to PubMed...
  9. Wen ZP, Fan SS, Du C, Yin T, Zhou BT, Peng ZF, et al. Drug-drug interaction between valproic acid and meropenem: a retrospective analysis of electronic medical records from neurosurgery inpatients. J Clin Pharm Ther. 2017;42(2):221-7. Go to original source... Go to PubMed...
  10. Doad G, McManus D, Topal J, Lopez F. 934: Utilizing the carbapenem­‑valproic acid drug interaction in the management of valproic acid overdose. Crit Care Med. 2018 Jan;46(1):450. Go to original source...
  11. Dreucean D, Beres K, McNierney­‑Moore A, Gravino D. Use of meropenem to treat valproic acid overdose. Am J Emerg Med. 2019 Nov 1;37(11):2120.e5-2120.e7. Go to original source... Go to PubMed...
  12. Cunningham D, Clark K, Lord K. Treatment of valproic acid overdose with meropenem in an epileptic patient. Am J Emerg Med. 2022 Mar;53:284.e1-284.e3. Go to original source... Go to PubMed...
  13. Thomas C, Priano J, Smith TL. Meropenem as an antidote for intentional valproic acid overdose. Am J Emerg Med. 2020 Mar;38(3):690.e1-690.e2. Go to original source... Go to PubMed...
  14. Teng R, Butler K. Effect of the CYP3A inhibitors, diltiazem and ketoconazole, on ticagrelor pharmacokinetics in healthy volunteers. J Drug Assess. 2013 Mar 15;2(1):30-9. Go to original source... Go to PubMed...
  15. Lexicomp® Drug Interactions [Internet]. UpToDate®. [cited 2023 Jul 20]. Available from: http://uptodate.com/drug­‑interactions/.
  16. Micromedex® Drug Interactions Results [Internet]. Merative Micromedex®. [cited 2023 Jul 20]. Available from: http://micromedex.fnusa.cz/micromedex2/librarian/PFDefault/evidencexpert.ShowDrugInteractionsResults.
  17. Gurbel PA, Bliden KP, Butler K, Tantry US, Gesheff T, Wei C, et al. Randomized Double­‑Blind Assessment of the ONSET and OFFSET of the Antiplatelet Effects of Ticagrelor Versus Clopidogrel in Patients With Stable Coronary Artery Disease. Circulation. 2009 Dec 22;120(25):2577-85. Go to original source... Go to PubMed...
  18. Butler K, Teng R. Pharmacokinetics, pharmacodynamics, safety and tolerability of multiple ascending doses of ticagrelor in healthy volunteers. Br J Clin Pharmacol. 2010 Jul;70(1):65-77. Go to original source... Go to PubMed...
  19. Charpentier T, Ferdynus C, Lair T, Cordier C, Brulliard C, Valance D, et al. Bleeding risk of ticagrelor compared to clopidogrel in intensive care unit patients with acute coronary syndrome: A propensity­‑score matching analysis. PLoS ONE. 2020 May 4;15(5):e0232768. Go to original source... Go to PubMed...
  20. Wallentin L, Becker RC, Budaj A, Cannon CP, Emanuelsson H, Held C, et al. Ticagrelor versus clopidogrel in patients with acute coronary syndromes. N Engl J Med. 2009 Sep 10;361(11):1045-57. Go to original source... Go to PubMed...
  21. Azran M, Tanaka KA. Interaction Between Ticagrelor and CYP3A4 Inhibitor: Importance of P2Y12 Function Testing to Assess Platelet Recovery Before Surgery. J Cardiothorac Vasc Anesth. 2019 Nov 1;33(11):3221-2. Go to original source... Go to PubMed...
  22. Dobesh PP, Oestreich JH. Ticagrelor: Pharmacokinetics, Pharmacodynamics, Clinical Efficacy, and Safety. Pharmacotherapy. 2014 Oct;34(10):1077-90. Go to original source... Go to PubMed...
  23. Weeks P, Sieg A, Vahdat K, Raissi F, Nathan S. Improved Ticagrelor Antiplatelet Effect on Discontinuation of Phenytoin. Ann Pharmacother. 2014 May 1;48(5):644-7. Go to original source... Go to PubMed...
  24. Nutt JG, Woodward WR, Carter JH, Trotman TL. Influence of fluctuations of plasma large neutral amino acids with normal diets on the clinical response to levodopa. J Neurol Neurosurg Psychiatry. 1989 Apr 1;52(4):481-7. Go to original source... Go to PubMed...
  25. Deleu D, Northway MG, Hanssens Y. Clinical Pharmacokinetic and Pharmacodynamic Properties of Drugs Used in the Treatment of Parkinson's Disease. Clin Pharmacokinet. 2002 Apr 1;41(4):261-309. Go to original source... Go to PubMed...
  26. Cooper MK, Brock DG, McDaniel CM. Interaction between levodopa and enteral nutrition. Ann Pharmacother. 2008 Mar;42(3):439-42. Go to original source... Go to PubMed...
  27. Leta V, Klingelhoefer L, Longardner K, Campagnolo M, Levent HÇ, Aureli F, et al. Gastrointestinal barriers to levodopa transport and absorption in Parkinson's disease. Eur J Neurol. 2023;30(5):1465-80. Go to original source... Go to PubMed...
  28. Bonnici A, Ruiner CE, St­‑Laurent L, Hornstein D. An interaction between levodopa and enteral nutrition resulting in neuroleptic malignant­‑like syndrome and prolonged ICU stay. Ann Pharmacother. 2010 Sep;44(9):1504-7. Go to original source... Go to PubMed...
  29. Whitman CB, Ablordeppey E, Taylor B. Levodopa Withdrawal Presenting as Fever in a Critically Ill Patient Receiving Concomitant Enteral Nutrition. J Pharm Pract. 2016 Dec 1;29(6):574-8. Go to original source... Go to PubMed...
  30. Vogelzang JMJ, Luinstra M, Rutgers AWF. Effect of Rectal Levodopa Administration: A Case Report. Case Rep Neurol. 2015 Oct 21;7(3):209-12. Go to original source... Go to PubMed...
  31. Josková V, Linhartová A. Levodopa (+ inhibitor dekarboxylázy) [Internet]. Doporučení pro podání léčiv sondou. 2021 [cited 2023 Jul 22]. Available from: https://www.coskf.cz/images/Dokumenty/Doporuceni_sondy/levodopa_s_inhibitorem_dekarboxylzy_-_doporuen.pdf.
  32. VandenBerg A, Broadway J. Enteral administration of protein supplement and valproate: A potential pharmacokinetic interaction. Ment Health Clin. 2018 Mar 23;7(1):10-2. Go to original source... Go to PubMed...
  33. Wohlt PD, Zheng L, Gunderson S, Balzar SA, Johnson BD, Fish JT. Recommendations for the use of medications with continuous enteral nutrition. Am J Health Syst Pharm. 2009 Aug 15;66(16):1458-67. Go to original source... Go to PubMed...
  34. Khatib R, Sabir FRN, Omari C, Pepper C, Tayebjee MH. Managing drug­‑induced QT prolongation in clinical practice. Postgrad Med J. 2021 Jul 1;97(1149):452-8. Go to original source... Go to PubMed...
  35. Tisdale JE, Jaynes HA, Kingery JR, Mourad NA, Trujillo TN, Overholser BR, et al. Development and Validation of a Risk Score to Predict QT Interval Prolongation in Hospitalized Patients. Circ Cardiovasc Qual Outcomes. 2013 Jul;6(4):479-87. Go to original source... Go to PubMed...
  36. Pickham D, Helfenbein E, Shinn JA, Chan G, Funk M, Weinacker A, et al. High prevalence of corrected QT interval prolongation in acutely ill patients is associated with mortality: Results of the QT in Practice (QTIP) Study. Crit Care Med. 2012 Feb;40(2):394. Go to original source... Go to PubMed...
  37. Indraratna P, Tardo D, Delves M, Szirt R, Ng B. Measurement and Management of QT Interval Prolongation for General Physicians. J Gen Intern Med. 2020 Mar 1;35(3):865-73. Go to original source... Go to PubMed...
  38. Elangovan A. QTc Prolongation in the Critically Ill: Tread with Caution! Indian J Crit Care Med. 2020 Apr;24(4):220-1. Go to original source... Go to PubMed...
  39. Ding Y, Jeon R, Ran L, Pan W, Wang F, Li Q. New­‑onset QT prolongation is a novel predictor of mortality in critically ill patients. Crit Care. 2019 Jun 21;23(1):229. Go to original source... Go to PubMed...
  40. Russell H, Churilov L, Toh L, Eastwood GM, Bellomo R. The incidence, predictors and outcomes of QTc prolongation in critically ill patients. J Crit Care. 2019 Dec 1;54:244-9. Go to original source... Go to PubMed...
  41. Javanainen T, Ishihara S, Gayat E, Charbit B, Jurkko R, Cinotti R, et al. Prolonged corrected QT interval is associated with short­‑term and long­‑term mortality in critically ill patients: results from the FROG­‑ICU study. Intensive Care Med. 2019 May 1;45(5):746-8. Go to original source... Go to PubMed...
  42. Shenthar J, Rachaiah JM, Pillai V, Chakali SS, Balasubramanian V, Chollenhalli Nanjappa M. Incidence of drug­‑induced torsades de pointes with intravenous amiodarone. Indian Heart J. 2017 Nov 1;69(6):707-13. Go to original source... Go to PubMed...
  43. QTDrugs Lists : Crediblemeds [Internet]. [cited 2023 Oct 15]. Available from: https://crediblemeds.org/druglist.
  44. Hasnain M, Vieweg WVR, Howland RH, Kogut C, Breden Crouse EL, Koneru JN, et al. Quetiapine, QTc interval prolongation, and torsade de pointes: a review of case reports. Ther Adv Psychopharmacol. 2014 Jun;4(3):130-8. Go to original source... Go to PubMed...
  45. Dube KM, DeGrado J, Hohlfelder B, Szumita PM. Evaluation of the Effects of Quetiapine on QTc Prolongation in Critically Ill Patients. J Pharm Pract. 2018 Jun;31(3):292-7. Go to original source... Go to PubMed...
  46. Zeppenfeld K, Tfelt­‑Hansen J, de Riva M, Winkel BG, Behr ER, Blom NA, et al. 2022 ESC Guidelines for the management of patients with ventricular arrhythmias and the prevention of sudden cardiac death. Eur Heart J. 2022 Oct 21;43(40):3997-4126. Go to original source... Go to PubMed...
  47. Grimm SW, Richtand NM, Winter HR, Stams KR, Reele SB. Effects of cytochrome P450 3 A modulators ketoconazole and carbamazepine on quetiapine pharmacokinetics. Br J Clin Pharmacol. 2006;61(1):58-69. Go to original source... Go to PubMed...
  48. Schulz­‑Du Bois C, Schulz­‑Du Bois AC, Bewig B, Gerstner I, Aldenhoff JB, Cascorbi I, et al. Major increase of quetiapine steady­‑state plasma concentration following co­‑administration of clarithromycin: confirmation of the pharmacokinetic interaction potential of quetiapine. Pharmacopsychiatry. 2008 Nov;41(6):258-9. Go to original source... Go to PubMed...
  49. Huang X, Zhou Y, Zhang J, Xiang H, Mei H, Liu L, et al. The importance of CYP2C19 genotype in tacrolimus dose optimization when concomitant with voriconazole in heart transplant recipients. Br J Clin Pharmacol. 2022;88(10):4515-25. Go to original source... Go to PubMed...
  50. Bakker T, Klopotowska JE, de Keizer NF, van Marum R, van der Sijs H, de Lange DW, et al. Improving medication safety in the Intensive Care by identifying relevant drug­‑drug interactions - Results of a multicenter Delphi study. J Crit Care. 2020 Jun;57:134-40. Go to original source... Go to PubMed...




Anesteziologie a intenzivní medicína

Madam, Sir,
please be aware that the website on which you intend to enter, not the general public because it contains technical information about medicines, including advertisements relating to medicinal products. This information and communication professionals are solely under §2 of the Act n.40/1995 Coll. Is active persons authorized to prescribe or supply (hereinafter expert).
Take note that if you are not an expert, you run the risk of danger to their health or the health of other persons, if you the obtained information improperly understood or interpreted, and especially advertising which may be part of this site, or whether you used it for self-diagnosis or medical treatment, whether in relation to each other in person or in relation to others.

I declare:

  1. that I have met the above instruction
  2. I'm an expert within the meaning of the Act n.40/1995 Coll. the regulation of advertising, as amended, and I am aware of the risks that would be a person other than the expert input to these sites exhibited


No

Yes

If your statement is not true, please be aware
that brings the risk of danger to their health or the health of others.